Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

TY - JOUR

T1 - Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

AU - MacDonald, T. M.

AU - Morant, S. V.

AU - Goldstein, J. L.

AU - Burke, T. A.

AU - Pettitt, D.

N1 - dc.publisher: BMJ Publishing Group dc.description.sponsorship: Pfizer Inc., New York, USA

PY - 2003

Y1 - 2003

N2 - Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.

AB - Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.

U2 - 10.1136/gut.52.9.1265

DO - 10.1136/gut.52.9.1265

M3 - Article

SN - 1468-3288

VL - 52

SP - 1265

EP - 1270

JO - Gut

JF - Gut

IS - 9

ER -